References
- Di Bisceglie A, Martin P, Kassianides C, Lisker‐Melman M, Murray L, Waggoner J, Goodman Z, Banks S, Hoofnagle J. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double‐blind, placebo‐controlled trial. N Engl J Med 1989; 321: 1506–1510
- Davis G, Balart L, Schiff E, Lindsay K, Bodenheimer H, Perillo R, Carey W, Jacobsson I, Payne J, Dienstag J, Van Thiel D, Tamburro C, Lefkowitsch J, Albrecht J, Meschievitz C, Ortego T, Gibas A, The Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–1506
- Schvarcz R, Weiland O, Wejstål R, Norkrans G, Frydén A, Foberg U. A randomized controlled open study of interferon alpha‐2b treatment of chronic non‐A, non‐B posttransfusion hepatitis: No correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989; 21: 617–625
- Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frydén A. Histological outcome in interferon alpha‐2b treated patients with chronic posttransfusion non‐A, non‐B hepatitis. Liver 1991; 11: 30–38
- Dienes H, Popper H, Arnold W, Lobeck H. Histologic observations in human hepatitis non‐A, non‐B. Hepatology 1982; 2: 562–571
- Ferenci P, Vogel W, Pristautz H, Deimer J, Denk H, Judmaier G, Maier K, Krejs G, Gangl A. One‐year treatment of chronic non‐A, non‐B hepatitis with interferon alfa‐2b. J Hepatol 1990; 11: 50–53, Suppl
- Realdi G, Diodati G, Bonetti P, Scaccabarozzi S, Alberti A, Ruol A. Recombinant human interferon alfa‐2a in community‐acquired non‐A, non‐B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J Hepatol 1990; 11: 68–71, Suppl
- Dienstag J. Non‐A, non‐B hepatitis I. Recognition, epidemiology, and clinical features. Gastroenterology 1983; 85: 439–462